NewLeaf Symbiotics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

newleafsym.com

Executives

6

Board of Directors

1

NewLeaf Symbiotics Board of Director

1 Board of directors

NewLeaf Symbiotics has 1 board of directors, including Jak Knowles.

Name

Firm

Work History

Other Seats

Jak Knowles

Dr. Jak Knowles serves as Metagenomi’s Chief Business Officer starting in October, 2020. Prior to joining Metagenomi, Jak was VP of Venture Investments at Leaps by Bayer where he helped lead Metagenomi’s initial seed financing and early strategy serving on Metagenomi’s Board of Directors. Prior to joining Bayer, Jak served as CEO of CytoSen Therapeutics, where he worked to develop Natural Killer cell immunotherapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company, serving as President and interim-CEO. Jak has a medical degree from Stanford University where he graduated with honors in biomedical research. Jak previously served on the Board of Directors for Century Therapeutics, Triumvira Immunologics, Pyxis Oncology, Vesigen Therapeutics, and Metagenomi Technologies.

NewLeaf Symbiotics

Name

Jak Knowles

Firm

Work History

Dr. Jak Knowles serves as Metagenomi’s Chief Business Officer starting in October, 2020. Prior to joining Metagenomi, Jak was VP of Venture Investments at Leaps by Bayer where he helped lead Metagenomi’s initial seed financing and early strategy serving on Metagenomi’s Board of Directors. Prior to joining Bayer, Jak served as CEO of CytoSen Therapeutics, where he worked to develop Natural Killer cell immunotherapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company, serving as President and interim-CEO. Jak has a medical degree from Stanford University where he graduated with honors in biomedical research. Jak previously served on the Board of Directors for Century Therapeutics, Triumvira Immunologics, Pyxis Oncology, Vesigen Therapeutics, and Metagenomi Technologies.

Other Seats

NewLeaf Symbiotics

NewLeaf Symbiotics Management Team

6 Team Members

NewLeaf Symbiotics has 6 executives. NewLeaf Symbiotics's founder is Tom Laurita. NewLeaf Symbiotics's current Chief Executive Officer is Stephen R Kahn.

Name

Work History

Title

Status

Tom Laurita

Founder

Current

Stephen R Kahn

Chief Executive Officer

Current

Desmond Jimenez

Novo Nordisk

Chief Product Officer

Current

Janne Kerovuo

Chief Technology Officer

Former

Gregg Bogosian

Chief Security Officer

Former

Name

Tom Laurita

Stephen R Kahn

Desmond Jimenez

Janne Kerovuo

Gregg Bogosian

Work History

Novo Nordisk

Title

Founder

Chief Executive Officer

Chief Product Officer

Chief Technology Officer

Chief Security Officer

Status

Current

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.